|Bid||9.46 x 1200|
|Ask||10.15 x 800|
|Day's range||9.73 - 10.06|
|52-week range||7.48 - 14.14|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.63|
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...
Puma Biotechnology reports inducement awards granted in May 2021 as required under Nasdaq Listing Rule 5635(c)(4) .
Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.